BiotechTube

Apixaban + Parenteral heparin and/or oral Vitamin K antagonist

ApprovedCompleted
1 views this week 0 watching⚡ Active
Interest: 43/100
43
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Atrial Fibrillation

Conditions

Atrial Fibrillation

Trial Timeline

Jul 14, 2014 → Feb 8, 2017

NCT ID
NCT02100228

About Apixaban + Parenteral heparin and/or oral Vitamin K antagonist

Apixaban + Parenteral heparin and/or oral Vitamin K antagonist is a approved stage product being developed by Pfizer for Atrial Fibrillation. The current trial status is completed. This product is registered under clinical trial identifier NCT02100228. Target conditions include Atrial Fibrillation.

What happened to similar drugs?

20 of 20 similar drugs in Atrial Fibrillation were approved

Approved (20) Terminated (4) Active (0)
✅OAC aloneDaiichi SankyoApproved
✅EdoxabanDaiichi SankyoApproved
✅Edoxaban + Aspirin and Clopidogrel + Aspirin and WarfarinDaiichi SankyoApproved
✅dapagliflozin + PlaceboAstraZenecaApproved
✅valsartanNovartisApproved
✅Vitamin K antagonist + ApixabanPfizerApproved
✅Apixaban + aspirinPfizerApproved

Hype Score Breakdown

Clinical
20
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT02100228ApprovedCompleted

Competing Products

20 competing products in Atrial Fibrillation

See all competitors
ProductCompanyStageHype Score
EdoxabanDaiichi SankyoPre-clinical
26
Edoxaban + Clopidogrel + Prasugrel + Ticagrelor + Vitamin K antagonistDaiichi SankyoPhase 3
40
OAC aloneDaiichi SankyoApproved
43
Edoxaban + ASADaiichi SankyoPhase 3
32
DU-176b tablets + DU-176b tablets + Warfarin tabletsDaiichi SankyoPhase 2
35
Edoxaban + Apixaban + RivaroxabanDaiichi SankyoPre-clinical
26
Edoxaban + VKA-Based Regimen + VKA-Based Regimen + VKA-Based Regimen + VKA-Based RegimenDaiichi SankyoPhase 3
40
Edoxaban (DU-176b) + Edoxaban (DU-176b) + Edoxaban (DU-176b) + Edoxaban (DU-176b) + warfarinDaiichi SankyoPhase 2
35
EdoxabanDaiichi SankyoPre-clinical
26
EdoxabanDaiichi SankyoApproved
43
Edoxaban + Warfarin + EnoxaparinDaiichi SankyoPhase 3
40
EdoxabanDaiichi SankyoPre-clinical
26
EdoxabanDaiichi SankyoPre-clinical
26
DU-176b 15mg + DU-176b 30mg + DU-176b 60mgDaiichi SankyoPhase 3
40
dabigatran, rivaroxaban, apixaban or edoxabanDaiichi SankyoPre-clinical
22
EdoxabanDaiichi SankyoPre-clinical
26
DU-176b tablets + Warfarin potassium tabletsDaiichi SankyoPhase 2
35
Edoxaban-based Regimen + VKA-based RegimenDaiichi SankyoPhase 3
40
EdoxabanDaiichi SankyoPre-clinical
26
Edoxaban + Aspirin and Clopidogrel + Aspirin and WarfarinDaiichi SankyoApproved
39